The introduction of imatinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has
dramatically changed the management of chronic myeloid leukemia (CML). More than …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is
highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more
potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL …

Abstract The translocation (9; 22) gives rise to the p190Bcr-Abl and p210Bcr-Abl tyrosine
kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive …

Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic
phase. We here describe the correlation of imatinib trough plasma concentrations (Cmins) …

Abstract Abstract 1126 Poster Board I-148 Background The IRIS study demonstrated
superior safety and efficacy of imatinib (IM) relative to interferon-αa+ cytarabine. Based on …

Imatinib mesylate is considered standard of care for first-line treatment of chronic phase
chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International …